Clarity Pharmaceuticals Ltd (ASX:CU6)
Australia · Delayed Price · Currency is AUD | Market Cap | 1.34B |
| Revenue (ttm) | 9.46M |
| Net Income (ttm) | -64.30M |
| Shares Out | 372.03M |
| EPS (ttm) | -0.20 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,240,004 |
| Average Volume | 2,483,526 |
| Open | 3.590 |
| Previous Close | 3.510 |
| Day's Range | 3.445 - 3.610 |
| 52-Week Range | 1.430 - 6.440 |
| Beta | 1.37 |
| RSI | 34.94 |
| Earnings Date | Nov 27, 2025 |
About Clarity Pharmaceuticals
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company’s lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; an... [Read more]
Financial Performance
In 2025, Clarity Pharmaceuticals's revenue was 9.46 million, a decrease of -17.76% compared to the previous year's 11.51 million. Losses were -64.30 million, 51.9% more than in 2024.
Financial StatementsNews
Clarity Pharma Co-PSMA Trial Meets Main Goal, Detects More Prostate Cancer Lesions Than Standard One
(RTTNews) - Clarity Pharmaceuticals (CU6.AX), a clinical-stage radiopharmaceutical company, announced that its Co-PSMA (NCT06907641) Investigator-Initiated Trial (IIT), led by Prof. Louise Emmett at S...
Greatland Resources, Clarity Pharma headline huge ASX 200 rebalance
The freshly listed gold miner is among a flurry of potential additions to the index as all the short sellers targeting the radiopharmaceutical may be rewarded.
Clarity Pharmaceuticals readies mega capital raising
Stockbroker Bell Potter in Melbourne is the sole lead manager on the deal, which is slated to launch on Monday.
Indoco Remedies stock surges 8% on partnership with Clarity Pharma in the UK
Indoco Remedies witnessed a significant 8% jump in its stock price following the announcement of a strategic distribution partnership with Clarity Pharma, UK. This collaboration is set to launch appro...
Indoco Remedies partners with Clarity Pharma to strengthen UK presence
The partnership combines Indoco’s robust portfolio of high-quality, affordable pharmaceutical products with Clarity Pharma’s extensive distribution network and market expertise.
Rising Shares at Clarity Pharmaceuticals as it Launches Second Phase III Trial and Promotes Michelle Parker to CEO
Biotech firm Clarity Pharmaceuticals is preparing to initiate a second Phase III clinical trial for its prostate cancer diagnostic product, 64Cu-SAR-bisPSMA, after receiving positive feedback from the...
Three ASX companies jockeying to be the next biotech winners
Clarity Pharmaceuticals reports it eliminated prostate cancer in a patient; LTR Pharma wants to sell nasal viagra; and Opthea has clinical trial results soon.